Moffitt Radiation Oncology Experts Share the Latest in Treatment and Research

By Kim Polacek, APR, CPRC - October 25, 2022

Nearly half of all cancer patients will receive radiation therapy during their treatment. This type of therapy has vastly improved over the past several decades, focused on more targeted, personalized treatment rather than radiating the whole body.

This progress is due to innovative clinical and scientific research. These advancements are presented at the American Society for Radiation Oncology (ASTRO) annual meeting each October. ASTRO is the largest radiation oncology society in the world, boasting nearly 10,000 physicians, nurses, biologists, physicists, radiation therapists, dosimetrists and other health care professionals who specialize in treating patients with radiation therapies. 

This year’s ASTRO annual meeting is focused on “AI & EI: Caring for the Patient in a Wireless World.” Thousands of experts traveled to San Antonio, Texas, to experience the more than 17,000 scientific presentations, clinical trial reports and special sessions.

Moffitt physicians and scientists participated in more than 20 presentations over the four-day conference. Their studies covered many different cancer types and radiation therapy modalities, such as stereotactic body radiotherapy for cervical cancer and MR-guided radiation therapy for lung cancer. To learn more about Moffitt’s presentations at ASTRO, visit and read the stories below.

Read Moffitt’s ASTRO 2022 Stories 

Can Higher Doses of Radiation Be Effective for Soft Tissue Sarcoma?

Acute toxicity can present challenges like skin redness and infections

DRIVE Study Offers New Treatment Options for Vulvar Cancer

Data shows radiation therapy as effective first line treatment

Can Bridging Radiation Therapy Increase Success of CAR T?

Moffitt study finds radiation prior to CAR T may increase survival in high-risk patients

Combining Targeted Radiotherapy with Immunotherapy May Improve Outcomes for Cervical Cancer Patients

Interim results from phase 2 clinical trial reveal responses to combination therapy

Contact the Author

Kim Polacek, APR, CPRC Senior PR Account Coordinator 813-456-3342 More Articles


Most Popular